Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7729378 | 0.98 | EPHX1 (0.43) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL6898174 | 0.98 | EPHX1 (0.43) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL6731887 | 0.98 | EPHX1 (0.43) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL6890147 | 0.95 | EPHX1 (0.40) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| SCHEMBL716430 | 0.88 | SIGMAR1 (0.48) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| SCHEMBL13912981 | 0.87 | SIGMAR1 (0.42) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| SCHEMBL1845767 | 0.87 | SIGMAR1 (0.47) | EPHX1SIGMAR1HPGDCYP1A2KDM1A | |
| Hydrochloric Acid SCHEMBL4312730 | 0.85 | SIGMAR1 (0.41) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| SCHEMBL13912980 | 0.84 | SIGMAR1 (0.39) | EPHX1SIGMAR1BCHEHPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL4315081 | 0.83 | SIGMAR1 (0.38) | EPHX1SIGMAR1BCHEHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| EP-2139837-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008116799-A1 | METHOD FOR PRODUCING FORMIC ACID | BASF SE (DE) | 2008-10-02 | — | — | WO | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0219765-B1 | MAGNETIC-RECORDING SUPPORT WITH DISPERSING AGENTS HARDENABLE BY RADIATION | Agfa-Gevaert AG (DE) | 1989-06-28 | — | — | EP | disclosed |
| US-4687709-A | UNSATURATED PHOSPHROIC ACID MIXTURES | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1987-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183232-A1 | 8-AZABICYCLO[3.2.1]OCTANE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | EPHX1 2848/4885SIGMAR1 6/4885BCHE 2727/4885 |
| US-11548887-B2 | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists | OPRM1, OPRD1, OPRK1 | EPHX1 2848/4885SIGMAR1 6/4885BCHE 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.